• PDF: Delivered by email usually within 48 UK business hours.

NicOx SA (COX) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:53

NicOx SA (COX) - Pharmaceuticals & Healthcare Deals and Alliances Profile

NicOx SA (COX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

NicOx SA (NicOx) is a publicly held France-based biopharmaceutical company. The company is principally engaged in the research, development and marketing of pharmaceuticals. The company primarily focuses on the development of internal portfolio of new chemical entities (NCEs) for the therapeutic areas of inflammation and cardio-metabolic. Its therapeutic areas include osteoarthritis, dyslipidemia, glaucoma, respiratory disorders, allergic rhinitis, hypertension, dermatology, diabetic retinopathy, cardio metabolic. NicOx has co-development agreements with Orexo AB, TOPIGEN Pharmaceuticals Inc. as well as, research alliances with Grupo Ferrer Internacional SA, Merck & Co., Inc. Its product portfolio comprises of Naproxcinod NCX 6560, NCX 116 (PF-03187207), TPI 1020, NCX 1510, NO-antihypertensives NCX 1047, NO-Donors in various stages of development and are developed based on the nitric oxide-donating technology. NicOx Research Institute SRL operates as a fully owned subsidiary of the company. NicOx and Bausch + Lomb, a eye health company, entered into a licensing agreement which grants Bausch + Lomb exclusive worldwide rights to develop and commerclise a nitric oxide-donating prostaglandin F2a-analog NCX 116 (previously PF-03187207). NicOx is headquartered in Sophia Antipolis, France.

NicOx SA (COX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.

This report covers the following industry codes:
SIC Code: 2834
NAICS Code: 325412

  • NicOx SA, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deal Details
    • Asset Purchase
    • NicOx Reacquires Rights To PF-03187207 For Glaucoma From Pfizer
    • NicOx Reacquires Rights To Nitric Oxide-Donating Compounds From Pfizer
    • NicOx Acquires Patents From NitroMed
    • Partnerships
    • NicOx Enters Into Option Agreement With Ferrer Internacional
    • NicOx Expands Research Collaboration With Merck & Co
    • NicOx Enters Into Co-Development Agreement With Grupo Ferrer
    • Merck & Co Enters Into An Agreement With NicOx
    • NicOx Signs Research Agreement With Pfizer
    • NicOx Extends Research Agreement With Merck
    • Licensing Agreements
    • NicOx Extends Ophthalmology Agreement With Pfizer
    • NicOx Enters Into Licensing Agreement With Pfizer
    • NicOx Enters Into Worldwide Licensing Agreement With Bausch & Lomb
    • Topigen Enters Into Licensing Agreement With NicOx
    • Equity Offering
    • NicOx Completes Rights Offering Of $105 Million
    • NicOx Completes Private Placement Of $45 Million
    • NicOx Completes Rights Offering Of $168 Million
    • NicOx Completes Private Placement Of $18 Million
    • NicOx Completes Private Placement Of $57 Million
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • Recent Developments
    • Strategy And Business Planning
    • Aug 04, 2010: NicOx To Close US Headquarters
    • May 19, 2010: NicOx Provides Strategic Update
    • Financial Announcements
    • Feb 24, 2011: NicOx Reports Net Loss Of €43.9m For 2010
    • Jul 30, 2010: NicOx Reports Net Loss Of EUR27.5 Million For H1 2010
    • May 07, 2010: NicOx Reports Net Loss Of EUR7.2 Million For Q1 2010
    • May 07, 2010: NicOx Reports Net Loss Of EUR7.2 Million For Q1 2010
    • Mar 04, 2010: NicOx Reports Net Loss Of EUR60.3 Million For 2009
    • Jul 29, 2009: NicOx Reports Net Loss Of EUR11.2 Million For Q1 2009
    • Jul 29, 2009: NicOx Reports Net Loss Of EUR27.2 Million For H1 2009
    • Government and Public Interest
    • Nov 18, 2009: FDA Accepts NDA For NicOx's Osteoporosis Drug
    • Sep 25, 2009: NicOx Submits NDA For Naproxcinod To The US FDA
    • Product News
    • Dec 22, 2009: NicOx Submits Marketing Authorization Application For Naproxcinod To EMEA
    • Nov 13, 2009: NicOx Presents Top-Line Results Of NCX 6560 Study
    • Nov 13, 2009: NicOx Reveals Updates On NO-Donating Atorvastatin Phase 1b Study
    • Apr 23, 2009: NicOx Acquires NitroMed's NO-Donating Patents
    • Jan 21, 2010: NicOx's Naproxcinod MAA Gets EMEA Validation
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 53
  • List of Tables
    • NicOx SA, Pharmaceuticals & Healthcare, Key Facts, 2009
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • NicOx SA, Deals By Therapy Area, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • NicOx Reacquires Rights To PF-03187207 For Glaucoma From Pfizer
    • NicOx Reacquires Rights To Nitric Oxide-Donating Compounds From Pfizer
    • NicOx Acquires Patents From NitroMed
    • NicOx Enters Into Option Agreement With Ferrer Internacional
    • NicOx Expands Research Collaboration With Merck & Co
    • NicOx Enters Into Co-Development Agreement With Grupo Ferrer
    • Merck & Co Enters Into An Agreement With NicOx
    • NicOx Signs Research Agreement With Pfizer
    • NicOx Extends Research Agreement With Merck
    • NicOx Extends Ophthalmology Agreement With Pfizer
    • NicOx Enters Into Licensing Agreement With Pfizer
    • NicOx Enters Into Worldwide Licensing Agreement With Bausch & Lomb
    • Topigen Enters Into Licensing Agreement With NicOx
    • NicOx Completes Rights Offering Of $105 Million
    • NicOx Completes Private Placement Of $45 Million
    • NicOx Completes Rights Offering Of $168 Million
    • NicOx Completes Private Placement Of $18 Million
    • NicOx Completes Private Placement Of $57 Million
    • NicOx SA, Key Employees
    • NicOx SA, Subsidiaries 44
  • List of Figures
    • NicOx SA, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals by Year, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • NicOx SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about NicOx SA (COX) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha